Literature DB >> 33496019

Non-Proteasomal Urine Activity in Bladder Cancer.

Natalia Gruba1, Lech Stachurski2, Adam Lesner1.   

Abstract

Bladder cancer (BC) is the sixth common cancer in the world, characterized by high recurrent rate and poor prognosis. In most cases is asymptomatic and it can take years until symptoms develop. What is more, diagnosed patients need regular re-examinations which are invasive and expensive. Here, we used chromogenic substrates for the qualitative determination of specific activity of urine enzymes in healthy and bladder cancer patients. The peptide ABZ-Met-Lys-Val-Trp-ANB-NH2 appears at low absorbance at 410 nm. During the hydrolysis, a free ANB-NH2 is released which has a maximum absorbance at 410 nm. Using the peptide, we identified proteolytic activity in the majority of urine samples collected from patients with diagnosed bladder cancer, while the proteolytic activity in urine samples from healthy volunteers was not detected.
© 2021 Wiley-VHCA AG, Zurich, Switzerland.

Entities:  

Keywords:  bladder cancer; chromogenic substrates; protease profiling; urine proteases

Mesh:

Substances:

Year:  2021        PMID: 33496019     DOI: 10.1002/cbdv.202000981

Source DB:  PubMed          Journal:  Chem Biodivers        ISSN: 1612-1872            Impact factor:   2.408


  1 in total

1.  A Novel Prognostic Signature Based on Ferroptosis-Related Genes Predicts the Prognosis of Patients With Advanced Bladder Urothelial Carcinoma.

Authors:  Xiaoqi Li; Junting Huang; Ji Chen; Yating Zhan; Rongrong Zhang; Enze Lu; Chunxue Li; Yuxiao Zhang; Yajing Wang; Yeping Li; Jianjian Zheng; Wujun Geng
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.